^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    LTK inhibitor

    Related drugs:
    9ms
    A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, Shouyao Holdings (Beijing) Co. LTD | Trial completion date: Dec 2025 --> May 2026 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    LTK (Leukocyte Receptor Tyrosine Kinase)
    |
    ficonalkib (SY-3505)
    9ms
    A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC (clinicaltrials.gov)
    P3, N=255, Not yet recruiting, Shouyao Holdings (Beijing) Co. LTD
    New P3 trial • Metastases
    |
    Xalkori (crizotinib) • ficonalkib (SY-3505)
    10ms
    Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/Ⅱ Study. (PubMed, J Thorac Oncol)
    Ficonalkib (SY-3505) was well tolerated, with favorable safety profiles and promising efficacy in patients resistant to prior 2-gen ALK TKI.
    Journal • Metastases
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    ficonalkib (SY-3505)
    1year
    A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, Shouyao Holdings (Beijing) Co. LTD
    New P1 trial • Metastases
    |
    LTK (Leukocyte Receptor Tyrosine Kinase)
    |
    ficonalkib (SY-3505)